Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_2996



Chemical Information
Antiviral agent IDDrugRepV_2996
Antiviral agent nameFlavaglines FL3
IUPAC Name(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-1,2,3,3a-tetrahydro-8bH-benzo[b]cyclopenta[d]furan-1,8b-diol PubChem
SMILES (isomeric)COc1cc2c(c(c1)OC)[C@@]3([C@@H](C[C@H]([C@@]3(O2)c4ccc(cc4)Br)c5ccccc5)O)O PubChem
Molecular FormulaC25H23BrO5 PubChem
Molecular Weight (g/mol)483.351 PubChem
InChlInChI=1S/C25H23BrO5/c1-29-18-12-20(30-2)23-21(13-18)31-25(16-8-10-17(26)11-9-16)19(14-22(27)24(23,25)28)15-6-4-3-5-7-15/h3-13,19,22,27-28H,14H2,1-2H3/t19-,22+,24+,25-/m0/s1 PubChem
Structural Information
  
Clinical Information
CategoryAnticancer
Biological Information
Secondary Indication Chikungunya virus (CHIKV) NA NAWorld Health OrganisationCDC
Secondary Indication (Approaches)Experimental
Secondary Indication (Methods)In-vitro
Secondary Indication (Model system) [cell lines/ animal models]HEK-293T/17
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)10 PFU/cell
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Time of drug delivery) Pre infection (1 hour)
Secondary Indication (Duration of drug delivery)20 hours
Secondary Indication (Drug concentration)20 nM
Secondary Indication (Cell based assay)Plaque assay
Secondary Indication (Change)Decrease
Secondary Indication (Type of Inhibition) Percentage inhibition [ 50 % ]
ReferenceWintachai P, Thuaud F, Basmadjian C, Roytrakul S, Ubol S, DÌÄå©saubry L, Smith DR..Assessment of flavaglines as potential chikungunya virus entry inhibitors..Microbiol Immunol. 2015 Mar;59(3):129-41. doi: 10.1111/1348-0421.12230. PMID:25643977 PubMed
CommentSynthetic sulfonyl amidines and flavaglines (FLs), a class of naturally occurring plant compounds with potent anti-cancer and cytoprotective and neuroprotective activities, have been shown to interact directly with prohibitin.